Status:
COMPLETED
Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders
Lead Sponsor:
Helwan University
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study aims to assess the role of ribavirin as an adjuvant to sofosbuvir/velpatasvir/voxilaprevir combination in retreatment of chronic hepatitis C with previous treatment failure.
Eligibility Criteria
Inclusion
- Adult (≥ 18 years) patients with chronic hepatitis C and detectable HCV RNA by Polymerase Chain Reaction (PCR) after completion of previous direct-acting antiviral regimen, and eligible for antiviral treatment.
Exclusion
- Patients with decompensated cirrhosis (Child-Pugh score B and C).
- Patients with platelet count less than 50000/ mm³.
- Patients with HCC or extrahepatic malignancy.
- Pregnancy or inability to use an effective contraceptive method.
Key Trial Info
Start Date :
November 21 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 21 2021
Estimated Enrollment :
281 Patients enrolled
Trial Details
Trial ID
NCT04695769
Start Date
November 21 2020
End Date
October 21 2021
Last Update
September 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of medicine Helwan University
Cairo, Egypt